Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Multiple Myeloma"" wg kryterium: Temat


Tytuł :
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Autorzy :
Costa LJ; Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. .
Derman BA; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
Bal S; Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Sidana S; Department of Medicine, Stanford University, Stanford, CA, USA.
Chhabra S; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Silbermann R; Division of Hematology and Medical Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.
Ye JC; Division of Hematology and Oncology, Department of Internal Medicine, Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
Cook G; Haematology & Myeloma Studies, Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Cornell RF; Division of Hematology & Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Holstein SA; Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Shi Q; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Omel J; Independent Patient Advocate, Omaha, NE, USA.
Callander NS; Carbone Cancer Center, University of Wisconsin, Madison, WI, USA.
Chng WJ; National University Health System, Singapore, Singapore.
Hungria V; Clinica São Germano, São Paulo, Brazil.
Maiolino A; Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Stadtmauer E; University of Pennsylvania, Philadelphia, PA, USA.
Giralt S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pasquini M; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Jakubowiak AJ; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
Morgan GJ; New York University Langone Health, New York, NY, USA.
Krishnan A; City of Hope, Duarte, CA, USA.
Jackson GH; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Mohty M; Hôpital Saint-Antoine, Paris, France.
Mateos MV; Department of Haematology, University Hospital of Salamanca, Salamanca, Spain.
Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Facon T; Service des Maladies du Sang, Centre Hospitalier Universitaire (CHU) Lille, University of Lille, Lille, France.
Spencer A; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VA, Australia.
Miguel JS; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada Instituto de Investigacion Sanitaria de Navarra, Pamplona, Spain.
Hari P; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Usmani SZ; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Charlotte, NC, USA.
Manier S; Department of Hematology, Université de Lille, CHU, Lille, France.
McCarthy P; Roswell Park Cancer Institute, Buffalo, NY, USA.
Kumar S; Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Gay F; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
Paiva B; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada Instituto de Investigacion Sanitaria de Navarra, Pamplona, Spain.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jan; Vol. 35 (1), pp. 18-30. Date of Electronic Publication: 2020 Aug 11.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Multiple Myeloma/*epidemiology
Multiple Myeloma/*pathology
Neoplasm, Residual/*diagnosis
Neoplasm, Residual/*epidemiology
Clinical Trials as Topic ; Diagnostic Imaging ; Disease Management ; Drug Collateral Sensitivity ; Global Health ; Humans ; Molecular Diagnostic Techniques/methods ; Molecular Diagnostic Techniques/standards ; Multiple Myeloma/therapy ; Neoplastic Cells, Circulating/metabolism ; Neoplastic Cells, Circulating/pathology ; Outcome Assessment, Health Care ; Population Surveillance ; Reproducibility of Results ; Smoldering Multiple Myeloma/epidemiology ; Smoldering Multiple Myeloma/pathology ; Time Factors
Czasopismo naukowe
Tytuł :
Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma.
Autorzy :
Ikeda S; Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Abe F; Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Matsuda Y; Department of Life Science, Akita University Graduate School of Engineering Science, Akita, Japan.
Kitadate A; Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Takahashi N; Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Tagawa H; Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Nov; Vol. 111 (11), pp. 4088-4101. Date of Electronic Publication: 2020 Sep 08.
Typ publikacji :
Journal Article
MeSH Terms :
Apoptosis/*genetics
Autophagy/*genetics
Hexokinase/*genetics
Hypoxia/*genetics
Hypoxia/*metabolism
Multiple Myeloma/*etiology
Multiple Myeloma/*metabolism
Animals ; Cell Hypoxia ; Cell Line, Tumor ; Disease Models, Animal ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Glycolysis ; Hexokinase/antagonists & inhibitors ; Hexokinase/metabolism ; Humans ; Mice ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Pyruvates/pharmacology ; Stress, Physiological ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors.
Autorzy :
Van Elssen C; Internal Medicine, Division of Hematology, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, Netherlands. .
van Gorkom G; Internal Medicine, Division of Hematology, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, Netherlands.
Voorter C; Department of Transplantation Immunology, Maastricht University Medical Center, Maastricht, Netherlands.
von dem Borne P; Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Meijer E; Department of Hematology, Amsterdam University Medical Center, Location VUMC, Cancer Center, Amsterdam, Netherlands.
Wieten L; Department of Transplantation Immunology, Maastricht University Medical Center, Maastricht, Netherlands.
Bos G; Internal Medicine, Division of Hematology, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, Netherlands.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jan; Vol. 100 (1), pp. 181-187. Date of Electronic Publication: 2020 Oct 28.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms :
Living Donors*
Killer Cells, Natural/*transplantation
Multiple Myeloma/*therapy
Transplantation, Haploidentical/*methods
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Prospective Studies ; Survival Rate/trends ; Transplantation, Homologous/methods
Czasopismo naukowe
Tytuł :
Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn.
Autorzy :
Koutsavlis I; NHS Fife, Haematology, Victoria Hospital, Kirkcaldy, KY2 5AH, UK. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Jan; Vol. 100 (1), pp. 1-10. Date of Electronic Publication: 2020 Oct 03.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunocompromised Host/*drug effects
Leukoencephalopathy, Progressive Multifocal/*drug therapy
Leukoencephalopathy, Progressive Multifocal/*immunology
Multiple Myeloma/*drug therapy
Multiple Myeloma/*immunology
Antibodies, Monoclonal/metabolism ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Humans ; Immunocompromised Host/physiology ; Immunologic Factors/metabolism ; Immunologic Factors/pharmacology ; Immunologic Factors/therapeutic use ; Leukoencephalopathy, Progressive Multifocal/metabolism ; Multiple Myeloma/metabolism
Czasopismo naukowe
Tytuł :
Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen.
Autorzy :
Szudy-Szczyrek A; Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081, Lublin, Poland. .
Mlak R; Chair and Department of Human Physiology, Medical University of Lublin, 20-080, Lublin, Poland.
Mielnik M; Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081, Lublin, Poland.
Szczyrek M; Chair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, 20-090, Lublin, Poland.
Nowaczyńska A; Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081, Lublin, Poland.
Homa-Mlak I; Chair and Department of Human Physiology, Medical University of Lublin, 20-080, Lublin, Poland.
Zmorzyński S; Department of Cancer Genetics with Cytogenetics Laboratory, Medical University of Lublin, 20-080, Lublin, Poland.
Kuśmierczuk K; Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081, Lublin, Poland.
Sompor J; Department of Traumatology and Emergency Medicine, Medical University of Lublin, 20-081, Lublin, Poland.
Filip A; Department of Cancer Genetics with Cytogenetics Laboratory, Medical University of Lublin, 20-080, Lublin, Poland.
Małecka-Massalska T; Chair and Department of Human Physiology, Medical University of Lublin, 20-080, Lublin, Poland.
Hus M; Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081, Lublin, Poland.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Dec; Vol. 99 (12), pp. 2881-2891. Date of Electronic Publication: 2020 May 26.
Typ publikacji :
Journal Article
MeSH Terms :
Blood Platelets/*metabolism
Lymphocytes/*metabolism
Multiple Myeloma/*blood
Multiple Myeloma/*drug therapy
Neutrophils/*metabolism
Thalidomide/*therapeutic use
Aged ; Blood Platelets/drug effects ; Female ; Follow-Up Studies ; Humans ; Immunosuppressive Agents/therapeutic use ; Lymphocyte Count/methods ; Lymphocytes/drug effects ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Neutrophils/drug effects ; Platelet Count/methods ; Prognosis ; Survival Rate/trends ; Thalidomide/pharmacology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany.
Autorzy :
Engelhardt M; Department of Internal Medicine I, Medical Center, University of Freiburg, Germany.
Shoumariyeh K; Department of Internal Medicine I, Medical Center, University of Freiburg, Germany.
Rösner A; Department of Internal Medicine I, Medical Center, University of Freiburg, Germany.
Ihorst G; Clinical Trials Unit Freiburg, Faculty of Medicine, University of Freiburg, Germany.
Biavasco F; Department of Internal Medicine I, Medical Center, University of Freiburg, Germany.
Meckel K; Julius Maximilians Universitaet, Würzburg, Germany.
von Metzler I; Universitätsklinik Frankfurt, Hematology and Oncology, Frankfurt, Germany.
Treurich S; Internal Medicine III, Ludwig-Maximilian-University Munich, University Hospital Munich, Germany.
Hebart H; Kliniken Ostalb, Stauferklinikum, Mutlangen, Germany.
Grube M; Hematology and Oncology, Uniklinik Regensburg, Germany.
Kull M; Hematology and Oncology, Uniklinik Ulm, Germany.
Bassermann F; Hematology and Oncology, Klinikum rechts der Isar, München, Germany.
Schäfer-Eckart K; Hematology and Oncology, Klinikum Nürnberg, Germany.
Hoferer A; Robert-Bosch-Krankenhaus, Stuttgart, Germany.
Einsele H; Julius Maximilians Universitaet, Würzburg, Germany.
Rasche L; Julius Maximilians Universitaet, Würzburg, Germany.
Wäsch R; Department of Internal Medicine I, Medical Center, University of Freiburg, Germany.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2020 Dec 01; Vol. 105 (12), pp. 2872-2878. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji :
Letter; Multicenter Study
MeSH Terms :
COVID-19/*complications
Multiple Myeloma/*mortality
Multiple Myeloma/*pathology
SARS-CoV-2/*isolation & purification
Aged ; Aged, 80 and over ; COVID-19/transmission ; COVID-19/virology ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma/therapy ; Multiple Myeloma/virology ; Prognosis ; Retrospective Studies ; Survival Rate
Raport
Tytuł :
Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study.
Autorzy :
Sunami K; Department of Hematology, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan. .
Murakami H; Department of Hematology, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan.
Tagashira H; Department of Pharmacy, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan.
Ueda H; Department of Hematology, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan.
Moriyama T; Department of Hematology, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan.
Ishikawa T; Department of Hematology, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan.
Yoshioka T; Department of Hematology, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan.
Makita M; Department of Hematology, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama, 701-1192, Japan.
Pokaż więcej
Źródło :
International journal of clinical oncology [Int J Clin Oncol] 2020 Dec; Vol. 25 (12), pp. 2151-2157. Date of Electronic Publication: 2020 Jul 26.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*drug therapy
Multiple Myeloma/*pathology
Adult ; Aged ; Aged, 80 and over ; Anemia/chemically induced ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Neutropenia/chemically induced ; Retrospective Studies ; Survival Rate ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
Autorzy :
Sunami K; Department of Hematology, National Hospital Organization, Okayama Medical Center, Okayama, Japan.
Suzuki K; Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan.
Ri M; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Matsumoto M; Department of Hematology, National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan.
Shimazaki C; Department of Hematology, Japan Community Health care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Asaoku H; Department of Hematology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Shibayama H; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Ishizawa K; Department of Third Internal Medicine, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan.
Takamatsu H; Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Ikeda T; Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan.
Maruyama D; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Kaneko H; Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Uchiyama M; Department of Hematology, Japanese Red Cross Society Suwa Hospital, Suwa, Japan.
Kiguchi T; Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan.
Iyama S; Department of Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Murakami H; Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Japan.
Takahashi K; Research and Development, Sanofi K.K., Tokyo, Japan.
Tada K; Research and Development, Sanofi K.K., Tokyo, Japan.
Macé S; Research and Development, Sanofi, Vitry, France.
Guillemin-Paveau H; Research and Development, Sanofi, Vitry, France.
Iida S; Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Dec; Vol. 111 (12), pp. 4526-4539. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Antineoplastic Agents/*administration & dosage
Multiple Myeloma/*drug therapy
ADP-ribosyl Cyclase 1/blood ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Confidence Intervals ; Drug Administration Schedule ; Female ; Humans ; Japan ; Male ; Maximum Tolerated Dose ; Membrane Glycoproteins/blood ; Middle Aged ; Multiple Myeloma/blood ; Multiple Myeloma/mortality ; Non-Randomized Controlled Trials as Topic ; Progression-Free Survival ; Recurrence ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Autorzy :
Susek KH; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Gran C; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, Sweden.
Ljunggren HG; Center for Infectious Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
Alici E; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Nahi H; Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute, Stockholm, Sweden.; Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło :
European journal of haematology [Eur J Haematol] 2020 Dec; Vol. 105 (6), pp. 751-754. Date of Electronic Publication: 2020 Aug 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Coronavirus Infections/*diagnosis
Dexamethasone/*adverse effects
Lenalidomide/*adverse effects
Multiple Myeloma/*diagnosis
Pneumonia, Viral/*diagnosis
Thalidomide/*adverse effects
Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Betacoronavirus/pathogenicity ; COVID-19 ; Cohort Studies ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Dexamethasone/administration & dosage ; Disease Progression ; Female ; Humans ; Immunomodulation ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Multiple Myeloma/mortality ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Prognosis ; Remission Induction ; SARS-CoV-2 ; Severity of Illness Index ; Survival Analysis ; Thalidomide/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity.
Autorzy :
Mountjoy L; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA.
Sebastian S; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA.
Jain T; Hematologic Malignancies and Bone Marrow Transplantation Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hilal T; Division of Hematology and Medical Oncology, University of Mississippi Medical Center, Jackson, MS, USA.
Gonzalez-Velez M; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA.
Girardo M; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Phoenix, AZ, USA.
Ahmann G; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA.
Larsen J; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA.
Bergsagel L; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA.
Fonseca R; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 3060-3063. Date of Electronic Publication: 2020 Jun 05.
Typ publikacji :
Letter
MeSH Terms :
Antineoplastic Agents/*pharmacology
Drug Resistance, Neoplasm/*drug effects
Immunologic Factors/*pharmacology
Multiple Myeloma/*immunology
Multiple Myeloma/*metabolism
Oxidative Stress/*drug effects
Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antioxidants/pharmacology ; Bone Marrow Cells/drug effects ; Bone Marrow Cells/metabolism ; Bone Marrow Cells/pathology ; Female ; Humans ; Immunologic Factors/therapeutic use ; Immunophenotyping ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy ; Oxidation-Reduction/drug effects ; Prognosis ; Treatment Outcome
Opinia redakcyjna
Tytuł :
Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?
Autorzy :
Junquera S; Department of Radiology, University Hospital of Santiago of Compostela, Santiago de Compostela, Spain. Electronic address: .
Álvarez-Yagüe E; Department of Oral and Maxillofacial Surgery, Central University Hospital of Asturias, Oviedo, Spain. Electronic address: .
Junquera L; Department of Oral and Maxillofacial Surgery, Central University Hospital of Asturias, Oviedo, Spain. Electronic address: .
Ugalde R; Department of Pathological Anatomy, Central University Hospital of Asturias, Oviedo, Spain. Electronic address: .
Rúa L; Department of Oral and Maxillofacial Surgery, University Hospital of Cabueñes, Gijón, Asturias, Spain. Electronic address: .
Pokaż więcej
Źródło :
Journal of stomatology, oral and maxillofacial surgery [J Stomatol Oral Maxillofac Surg] 2020 Nov; Vol. 121 (5), pp. 523-526. Date of Electronic Publication: 2019 Dec 18.
Typ publikacji :
Journal Article
MeSH Terms :
Bisphosphonate-Associated Osteonecrosis of the Jaw*/diagnosis
Bisphosphonate-Associated Osteonecrosis of the Jaw*/epidemiology
Bisphosphonate-Associated Osteonecrosis of the Jaw*/etiology
Multiple Myeloma*/complications
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Diphosphonates/adverse effects ; Humans ; Retrospective Studies ; Zoledronic Acid/adverse effects
Czasopismo naukowe
Tytuł :
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.
Autorzy :
Shah V; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Sherborne AL; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Johnson DC; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Ellis S; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Price A; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Chowdhury F; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Kendall J; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Jenner MW; Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Drayson MT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Owen RG; Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.
Gregory WM; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Morgan GJ; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Davies FE; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Cook G; Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Cairns DA; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Houlston RS; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.; Molecular and Population Genetics, The Institute of Cancer Research, London, UK.
Jackson G; Department of Haematology, University of Newcastle, Newcastle Upon Tyne, UK.
Kaiser MF; Division of Molecular Pathology, The Institute of Cancer Research, London, UK. .
Pokaż więcej
Corporate Authors :
on behalf of NCRI Haematology Clinical Studies Group
Źródło :
Leukemia [Leukemia] 2020 Nov; Vol. 34 (11), pp. 3091-3096. Date of Electronic Publication: 2020 Mar 11.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Profiling*
Transcriptome*
Multiple Myeloma/*diagnosis
Multiple Myeloma/*genetics
Biomarkers, Tumor ; Chromosome Aberrations ; Humans ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Prognosis ; Proportional Hazards Models ; Stem Cell Transplantation
Raport
Tytuł :
SARS-CoV-2 in multiple myeloma: initial observation and management.
Autorzy :
Manasanch EE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mulanovich V; Department of Internal Medicine/Infectious Disease, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manzano JG; Department of Internal Medicine/Infectious Disease, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gaeta MS; Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Becnel M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kaufman GP; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amini B; Radiodiagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thomas SK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Iyer SP; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Weber DM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Berkova Z; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Flowers CR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patel KK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2020 Nov; Vol. 61 (11), pp. 2763-2766. Date of Electronic Publication: 2020 Jun 17.
Typ publikacji :
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Coronavirus Infections/*complications
Multiple Myeloma/*therapy
Multiple Myeloma/*virology
Pneumonia, Viral/*complications
Aged ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/transmission ; Coronavirus Infections/virology ; Disease Management ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/complications ; Multiple Myeloma/diagnosis ; Pandemics ; Pneumonia, Viral/transmission ; Pneumonia, Viral/virology ; Prognosis ; SARS-CoV-2
Raport
Tytuł :
Metabolic markers for diagnosis and risk-prediction of multiple myeloma.
Autorzy :
Fei F; Phase I Clinical Trials Unit, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321#, Gulou district, Nanjing 210008, China.
Ma T; Phase I Clinical Trials Unit, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321#, Gulou district, Nanjing 210008, China.
Zhou X; Phase I Clinical Trials Unit, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321#, Gulou district, Nanjing 210008, China.
Zheng M; Phase I Clinical Trials Unit, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321#, Gulou district, Nanjing 210008, China.
Cao B; Phase I Clinical Trials Unit, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321#, Gulou district, Nanjing 210008, China. Electronic address: .
Li J; Phase I Clinical Trials Unit, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321#, Gulou district, Nanjing 210008, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Jan 15; Vol. 265, pp. 118852. Date of Electronic Publication: 2020 Dec 02.
Typ publikacji :
Journal Article
MeSH Terms :
Metabolomics*
Biomarkers, Tumor/*metabolism
Bone Marrow/*metabolism
Multiple Myeloma/*diagnosis
Adult ; Aged ; Case-Control Studies ; Female ; Gas Chromatography-Mass Spectrometry ; Glutamic Acid/metabolism ; Humans ; Male ; Metabolome ; Middle Aged ; Multiple Myeloma/metabolism ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Autorzy :
Usmani SZ; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. Electronic address: .
Hoering A; Cancer Research And Biostatistics, Seattle, WA, USA.
Ailawadhi S; Mayo Clinic, Jacksonville, FL, USA.
Sexton R; Cancer Research And Biostatistics, Seattle, WA, USA.
Lipe B; University of Rochester Medical Center, Rochester, NY, USA.
Hita SF; SWOG Operations Office, San Antonio, TX, USA.
Valent J; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Rosenzweig M; City of Hope, Los Angeles, CA, USA.
Zonder JA; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Dhodapkar M; Emory University Cancer Institute, Atlanta, GA, USA.
Callander N; University of Wisconsin Cancer Center, Madison, WI, USA.
Zimmerman T; Department of Hematology Oncology, University of Chicago, Chicago, IL, USA; BeiGene Pharma, Chicago, IL, USA.
Voorhees PM; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Durie B; Cedar-Sinai Medical Center, Los Angeles, CA, USA.
Rajkumar SV; Mayo Clinic, Rochester, MN, USA.
Richardson PG; Dana Farber Cancer Institute, Boston, MA, USA.
Orlowski RZ; MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Corporate Authors :
SWOG1211 Trial Investigators
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Jan; Vol. 8 (1), pp. e45-e54. Date of Electronic Publication: 2020 Dec 22.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Multiple Myeloma*/drug therapy
Multiple Myeloma*/genetics
Multiple Myeloma*/metabolism
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease-Free Survival ; Female ; Humans ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Maintenance Chemotherapy ; Male ; Middle Aged ; Survival Rate
Czasopismo naukowe
Tytuł :
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
Autorzy :
García-Guerrero E; Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
Götz R; Department of Biotechnology and Biophysics, Biocenter, and RVZ for Integrative and Translational BioImaging, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
Doose S; Department of Biotechnology and Biophysics, Biocenter, and RVZ for Integrative and Translational BioImaging, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
Sauer M; Department of Biotechnology and Biophysics, Biocenter, and RVZ for Integrative and Translational BioImaging, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
Rodríguez-Gil A; Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
Nerreter T; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Kortüm KM; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Pérez-Simón JA; Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
Einsele H; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Hudecek M; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Danhof S; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jan; Vol. 35 (1), pp. 201-214. Date of Electronic Publication: 2020 Apr 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
ADP-ribosyl Cyclase 1/*genetics
Antibodies, Monoclonal/*pharmacology
Antineoplastic Agents/*pharmacology
Gene Expression Regulation, Neoplastic/*drug effects
Histone Deacetylase 6/*antagonists & inhibitors
Histone Deacetylase Inhibitors/*pharmacology
Membrane Glycoproteins/*genetics
Multiple Myeloma/*genetics
ADP-ribosyl Cyclase 1/metabolism ; Antibody-Dependent Cell Cytotoxicity/drug effects ; Antibody-Dependent Cell Cytotoxicity/immunology ; Cell Line, Tumor ; Drug Synergism ; Histone Deacetylase Inhibitors/therapeutic use ; Humans ; Hydroxamic Acids/pharmacology ; Immunophenotyping ; Membrane Glycoproteins/metabolism ; Models, Biological ; Multiple Myeloma/drug therapy ; Multiple Myeloma/metabolism ; Pyrimidines/pharmacology ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism
Czasopismo naukowe
Tytuł :
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Autorzy :
Hose D; Division of Hematology, Wuerzburg University Medical Center, Würzburg, Germany.
Schreder M; Division of Hematology, Wuerzburg University Medical Center, Würzburg, Germany.
Hefner J; Division of Psychosomatic Medicine, Wuerzburg University Medical Center, Würzburg, Germany.
Bittrich M; Division of Hematology, Wuerzburg University Medical Center, Würzburg, Germany.
Danhof S; Division of Hematology, Wuerzburg University Medical Center, Würzburg, Germany.
Strifler S; Division of Hematology, Wuerzburg University Medical Center, Würzburg, Germany.
Krauth MT; Department of Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria.
Schoder R; Department of Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria.
Gisslinger B; Department of Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria.
Einsele H; Division of Hematology, Wuerzburg University Medical Center, Würzburg, Germany.
Gisslinger H; Department of Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria.
Knop S; Division of Hematology, Wuerzburg University Medical Center, Würzburg, Germany. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Jan; Vol. 147 (1), pp. 205-212. Date of Electronic Publication: 2020 Jul 18.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*drug therapy
Academic Medical Centers ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Dexamethasone/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Prognosis ; Remission Induction ; Retrospective Studies ; Survival Rate ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives
Czasopismo naukowe
Tytuł :
Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients.
Autorzy :
Covut F; Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Driscoll JJ; Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.; Case Western Reserve University, Cleveland, OH, USA.
Cooper B; Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.; Case Western Reserve University, Cleveland, OH, USA.
Gallogly M; Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.; Case Western Reserve University, Cleveland, OH, USA.
De Lima M; Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.; Case Western Reserve University, Cleveland, OH, USA.
Malek E; Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. .; Case Western Reserve University, Cleveland, OH, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jan; Vol. 35 (1), pp. 250-254. Date of Electronic Publication: 2020 May 24.
Typ publikacji :
Letter
MeSH Terms :
Healthcare Disparities*
Outcome Assessment, Health Care*
Multiple Myeloma/*epidemiology
Age Factors ; Continental Population Groups ; Humans ; Multiple Myeloma/diagnosis ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Odds Ratio
Opinia redakcyjna
Tytuł :
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.
Autorzy :
Ludwig H; Wilhelminen Cancer Research Institute, c/o 1st Department of Medicine, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria. .
Boccadoro M; Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.
Moreau P; Service hematologie et thérapie cellulaire, PRC. cic 1402 Inserm, CHU poitiers, Poitiers, France.
San-Miguel J; CIMA, IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Spain.
Cavo M; Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
Pawlyn C; The Institute of Cancer Research, London, UK.
Zweegman S; Department of Hematology, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
Facon T; Hôpital Claude Huriez, Lille University Hospital, Lille, France.
Driessen C; Department of Medical Oncology and Hematology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
Hajek R; Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Dimopoulos MA; Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Gay F; Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.
Avet-Loiseau H; Unité de Génomique du Myélome, University of Toulouse, Toulouse, France.
Terpos E; Hematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Zojer N; 1st Department of Medicine, Center for Hematology, Oncology, and Palliatic Care, Clinic Ottakring, Vienna, Austria.
Mohty M; Department of Clinical Hematology and Cellular Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France.
Mateos MV; IBSAL, Cancer Research Center, University Hospital of Salamanca, Salamanca, Spain.
Einsele H; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Delforge M; Department of Hematology, UZ Leuven, Leuven, Belgium.
Caers J; Department of Clinical Hematology, CHU of Liège, Liège, Belgium.
Weisel K; II. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Jackson G; NCCC, Newcastle upon Tyne Hospitals Trust, Newcastle upon Tyne, UK.
Garderet L; INSERM, UMR_S 938, Centre de Recherche Saint-Antoine-Team Proliferation and Differentiation of Stem Cells, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Service d'Hématologie, Sorbonne Université, Paris, France.
Engelhardt M; Interdisciplinary Tumor Center, Faculty of Freiburg, University of Freiburg, Freiburg, Germany.
van de Donk N; Department of Hematology, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
Leleu X; Poitiers University Hospital, Poitiers, France.
Goldschmidt H; Internal Medicine V and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Beksac M; Department of Hematology, Ankara University, Ankara, Turkey.
Nijhof I; Department of Hematology, Amsterdam UMC, VU University, Amsterdam, The Netherlands.
Abildgaard N; Department of Hematology, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
Bringhen S; Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy.
Sonneveld P; Erasmus MC Cancer Institute, Erasmus University of Rotterdam, Rotterdam, The Netherlands.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jan; Vol. 35 (1), pp. 31-44. Date of Electronic Publication: 2020 Aug 19.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Communicable Disease Control*
Practice Guidelines as Topic*
Vaccination*
Communicable Diseases/*etiology
Multiple Myeloma/*complications
Vaccines/*administration & dosage
Clinical Trials as Topic ; Consensus ; Europe ; Humans ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Multiple Myeloma/immunology ; Multiple Myeloma/therapy
Czasopismo naukowe
Tytuł :
Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation.
Autorzy :
Vaxman I; Division of Hematology, Mayo Clinic, Rochester, Minnesota.; Davidoff Cancer Center, Rabin Medical Center Petah-Tikva, Institute of Hematology, Petah-Tikva, Israel.; Sackler Faculty of Medicine Tel-Aviv University, Tel-Aviv, Israel.
Visram A; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Kapoor P; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Kumar S; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Buadi F; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Dingli D; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Muchtar E; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Gonsalves W; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Rajkumar V; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Kourelis T; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Warsame R; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Lacy M; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Gertz MA; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Jan; Vol. 96 (1), pp. E35-E38. Date of Electronic Publication: 2020 Nov 02.
Typ publikacji :
Clinical Trial; Letter
MeSH Terms :
Chromosome Deletion*
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/genetics
Multiple Myeloma*/mortality
Multiple Myeloma*/therapy
Smith-Magenis Syndrome*
Adult ; Aged ; Autografts ; Chromosomes, Human, Pair 17 ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Survival Rate
SCR Disease Name :
Chromosome 17 deletion
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies